and speaker fees from Novo Nordisk Boehringer Ingelheim and Bayer
1 Introduction In the past decade, obesity and related co-morbidities have become critical public health problems and serious medical conditions worldwide (1)
Kennedy has already insinuated that the use of GLP-1s in children could raise the specter of unforeseen problems that interrupt, damage, or impair metabolism and growth development, in his controversial MAHA Report
Consent for publication: Not applicable: Our review did not involve collection of new patient data
Additionally, the superiority of GLP-1RAs compared to placebo in the primary endpoint of 3-MACE were found with liraglutide in the LEADER trial (HR 0.87
As for clinical outcomes, in the T2DM group, there was a significant reduction in HbA1c (decreased by 1.01% to 1.02%, placebo-adjusted) and a clinically meaningful decrease in body weight of 3.26% to 3.51% after 12 weeks of treatment